NLRP3 Inflammasome-Mediated Pyroptosis in Diabetic Nephropathy: Pathogenic Mechanisms and Therapeutic Targets
Authors:
Open Access
- 1 June 2025
- journal article
- review article
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 8399-8418
Abstract
Diabetic nephropathy (DN) is a prevalent microangiopathic manifestation of diabetes mellitus (DM) and a pathological sequela of chronic glycemic disorders, characterized by several pathological features including glomerulosclerosis, podocyte loss, tubular epithelial atrophy and abnormal extracellular matrix accumulation. A growing body of research has underscored that chronic inflammatory microenvironments play a central role in the progression of DN. Pyroptosis, a newly defined form of programmed inflammatory necrosis, operates through the following molecular mechanism: inflammasome activation, gasdermin D (GSDMD)-mediated plasma membrane perforation and pro-inflammatory mediator release. Pyroptosis is triggered by the activation of the NOD-like receptor 3 (NLRP3) inflammasome. Classical (caspase-1) or non-classical (caspase-4/5/11) pathways activate pyroptosis by cleaving GSDMD, inducing enzymatic fragmentation of the GSDMD protein. GSDMD-N-terminal domain oligomerizes to form transmembrane pores, which further disrupt cellular osmotic homeostasis as well as membrane integrity. Inflammatory cascades are triggered when IL-1 and IL-18 are released as a result of subsequent cell lysis. This review systematically elucidates the pathobiological interplay between pyroptosis regulatory networks and the pathogenesis of DN and summarizes potential therapeutic compounds that mitigate pyroptosis by inhibiting NLRP3 inflammasome activation or blocking GSDMD pore formation. Preclinical studies suggest that targeting pyroptosis-related signaling molecules including NLRP3, caspase-1 and GSDMD may alleviate renal injury by suppressing inflammation-driven fibrosis and ameliorating glomerular dysfunction. Current studies emphasize that regulating pyroptosis mechanisms could slow DN progression, providing novel insights into the development of nephroprotective strategies.Keywords
This publication has 251 references indexed in Scilit:
- Programmed cell death: molecular mechanisms, biological functions, diseases, and therapeutic targetsMedcomm, 2024
- Diabetes mellitus, the fastest growing global public health concern: Early detection should be focusedHealth Science Reports, 2024
- GLP-1RAs inhibit the activation of the NLRP3 inflammasome signaling pathway to regulate mouse renal podocyte pyroptosisActa Diabetologica, 2023
- Syringaresinol Protects against Type 1 Diabetic Cardiomyopathy by Alleviating Inflammation Responses, Cardiac Fibrosis, and Oxidative StressMolecular Nutrition & Food Research, 2020
- Autophagy and Diabetic Nephropathy2020
- LncRNA MALAT1 promoted high glucose‐induced pyroptosis of renal tubular epithelial cell by sponging miR‐30c targeting for NLRP3The Kaohsiung Journal of Medical Sciences, 2020
- Cell death: a review of the major forms of apoptosis, necrosis and autophagyCell Biology International, 2019
- Triptolide prevents extracellular matrix accumulation in experimental diabetic kidney disease by targeting microRNA‐137/Notch1 pathwayJournal of Cellular Physiology, 2017
- Caspase‐11 activates a canonical NLRP3 inflammasome by promoting K+ effluxEuropean Journal of Immunology, 2015
- Glomerular basement membrane composition and the filtration barrierPediatric Nephrology, 2011